What Did STAR*D Teach Us? Results From a Large-Scale, Practical, Clinical Trial for Patients With Depression
The DOI matches its Crossref record.
Abstract
The authors provide an overview of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (www.star-d.org), a large-scale practical clinical trial to determine which of several treatments are the most effective "next-steps" for patients with major depressive disorder whose symptoms do not remit or who cannot tolerate an initial treatment and, if needed, ensuing treatments. Entry criteria were broadly defined and inclusive, and patients were enrolled from psychiatric and primary care clinics. All participants began on citalopram and were managed by clinic physicians, who followed an algorithm-guided acute-phase treatment through five visits over 12 weeks. At the end of each sequence, patients whose depression had not fully remitted were eligible for subsequent randomized trials in a sequence of up to three clinical trials. In general, remission rates in the study clinics were lower than expected, suggesting the need for several steps to achieve remission for most patients. There was no clear medication "winner" for patients whose depression did not remit after one or more aggressive medication trials. Both switching and augmenting appeared to be reasonable options when an initial antidepressant treatment failed, although these two strategies could not be directly compared. Further, the likelihood of remission after two vigorous medication trials substantially decreased, and remission would likely require more complicated medication regimens for which the existing evidence base is quite thin. STAR*D demonstrated that inclusion of more real-world patients in clinical trials is both feasible and informative. Policy implications of the findings, as well as the study's limitations, are discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“low efficacy (only 27% of depressed patients achieved remission after 12 weeks of citalopram treatment as measured by HAM-D)”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [259]
In the citing paper
“the current standard of care treatments suffer from slow onset (e.g., 7 week average response time with citalopram)”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [259]
In the citing paper
“Studies examining antidepressant efficacy reveal 30% of depressed patients fail to respond to common antidepressant treatment (1)”
From Emerging Role for Nucleus Accumbens Medium Spiny Neuron Subtypes in Depression (2017) · cites this paper as [1]
In the citing paper
“Currently available antidepressant medications, alone and in combination, are associated with high rates of partial- or non-response, delayed response onset of weeks to months, and limited duration of efficacy5.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [5]
In the citing paper
“while more than a third fail to achieve remission even after several rounds of treatment ( Al-Harbi, 2012 , Gaynes et al., 2009 , Strawbridge et al., 2022 )”
From Self-blame-selective hyper-connectivity between anterior temporal and subgenual cortices predicts prognosis in major depressive disorder (2023) · cites this paper as Gaynes et al., 2009
Citations
Cites
Still being checked.
Cited by
Items 201–300 of 764
Hietamies, T. M., McInnes, L. A., Klise, A., Worley, M. J., Qian, J. J., Williams, L. M., Heifets, B. D., & Levine, S. P. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.04.141 · Cited by 35
Hoertel, N., Strat, Y. L., de Maricourt, P., Limosin, F., & Dubertret, C. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.09.023 · Cited by 35
Haley, C. L., Sung, S. C., Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Luther, J. F., & Kornstein, S. G. (2013) · Journal of Women s Health · doi:10.1089/jwh.2011.3186 · Cited by 35
Self-citationFisher, S. D., Sit, D. K. Y., Yang, A., Ciolino, J. D., Gollan, J. K., & Wisner, K. L. (2019) · Depression and Anxiety · doi:10.1002/da.22879 · Cited by 36
Modulation of the functional connectome in major depressive disorder by ketamine therapy
Sahib, A. K., Loureiro, J. R., Vasavada, M. M., Anderson, C., Kubicki, A., Wade, B., Joshi, S. H., Woods, R. P., Congdon, E. L., Espinoza, R. T., et al. (2020) · Psychological Medicine · doi:10.1017/s0033291720004560 · Cited by 35
Peripheral mitochondrial DNA as a neuroinflammatory biomarker for major depressive disorder
Ye, J., Duan, C., Han, J., Chen, J., Sun, N., Li, Y., Yuan, T., & Peng, D. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01878 · Cited by 35
Depression with immuno-metabolic dysregulation: Testing pragmatic criteria to stratify patients
Zwiep, J. C., Milaneschi, Y., Giltay, E. J., Vinkers, C. H., Penninx, B. W. J. H., & Lamers, F. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.11.033 · Cited by 34
A New Paradigm for Achieving a Rapid Antidepressant Response
Malhi, G. S., Morris, G., Bell, E., & Hamilton, A. (2020) · Drugs · doi:10.1007/s40265-020-01303-1 · Cited by 34
Mishra, P. K., Adusumilli, M., Deolal, P., Mason, G. F., Kumar, A., & Patel, A. B. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104750 · Cited by 34
Jiang, C., Zhou, T. G., Chen, W., Lin, D., Guo, A., Liu, Z., & Fei, E. (2020) · Biology · doi:10.3390/biology9110359 · Cited by 34
Okada, M., Matsumoto, R., Yamamoto, Y., & Fukuyama, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031351 · Cited by 34
Depression in the Primary Care Setting
Ellis, P., Kitay, B. M., & Schmidt, C. J. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1903259 · Cited by 34
Vignaud, P., Donde, C., Sadki, T., Poulet, E., & Brunelin, J. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.03.004 · Cited by 33
Dominiak, M., Antosik-Wójcińska, A. Z., Goetz, Z., Sikorska, O., Stefanowski, B., Gorostiza, D., & Święcicki, Ł. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.12.002 · Cited by 34
Ulbricht, C. M., Rothschild, A. J., & Lapane, K. L. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.08.039 · Cited by 33
Major Depressive Disorder: New Clinical, Neurobiological, and Treatment Perspectives
Kupfer, D. J., Frank, E., & Phillips, M. L. (2016) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.140208 · Cited by 33
Poleshuck, E. L., Mazzotta, C. M., Resch, K., Rogachefsky, A., Bellenger, K., Raimondi, C., Stone, J. T., & Cerulli, C. (2016) · Journal of Interpersonal Violence · doi:10.1177/0886260516628810 · Cited by 34
A sham-controlled randomized trial of adjunctive light therapy for non-seasonal depression
Chojnacka, M., Antosik-Wójcińska, A. Z., Dominiak, M., Bzinkowska, D., Borzym, A., Sokół-Szawłowska, M., Bodzak-Opolska, G., Antoniak, D., & Święcicki, Ł. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.05.062 · Cited by 32
Rosas-Sánchez, G. U., Germán-Ponciano, L. J., Puga-Olguín, A., Flores-Soto, M. E., Nápoles-Medina, A. Y., Muñoz‐Carrillo, J. L., Rodríguez‐Landa, J. F., & Soria-Fregozo, C. (2025) · Biomedicines · doi:10.3390/biomedicines13081831 · Cited by 33
Okada, M., Kawano, Y., Fukuyama, K., Motomura, E., & Shiroyama, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217951 · Cited by 32
Predicting Depression in Community Dwellers Using a Machine Learning Algorithm
Cho, S., Geem, Z. W., & Na, K. (2021) · Diagnostics · doi:10.3390/diagnostics11081429 · Cited by 32
Social stress induces autoimmune responses against the brain
Shimo, Y., Cathomas, F., Lin, H., Chan, K. L., Parise, L. F., Li, L., Perez, C. F., Muhareb, S., Costi, S., Murrough, J. W., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2305778120 · Cited by 32
On the significance of elektroconvulsive therapy in the treatment of severe mental diseases
Grözinger, M., Smith, E. S., & Conca, A. (2015) · Wiener klinische Wochenschrift · doi:10.1007/s00508-015-0749-z · Cited by 33
Hoertel, N., de Maricourt, P., Katz, J., Doukhan, R., Lavaud, P., Peyre, H., & Limosin, F. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000204 · Cited by 27
Delaveau, P., Sanchez, T. A., Steffen, R. E., Deschet, K., Jabourian, M., Perlbarg, V., Gasparetto, E. L., Dubal, S., Silva, J. C. E., & Fossati, P. (2017) · Human Brain Mapping · doi:10.1002/hbm.23603 · Cited by 34
First Descents, an adventure program for young adults with cancer: who benefits?
Zebrack, B., Kwak, M., & Sundstrom, L. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3792-7 · Cited by 34
Do Statins Have Antidepressant Effects?
Köhler-Forsberg, O., Gasse, C., Berk, M., & Østergaard, S. D. (2017) · CNS Drugs · doi:10.1007/s40263-017-0422-3 · Cited by 31
P300 parameters in major depressive disorder: A systematic review and meta-analysis
Arıkan, M. K., İlhan, R., Orhan, Ö., Esmeray, M. T., Turan, Ş., Gıca, Ş., Bakay, H., Pogarell, O. M., Tarhan, N., & Metin, B. (2024) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2024.2321554 · Cited by 31
Cai, M.-Y., Yang, Z., Huang, X., Li, J., Bao, W.-Y., Hurilebagen, Wulanqiqige, Wuyunsiriguleng, Cui, J.-W., Ma, L., et al. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115310 · Cited by 31
Zwiep, J. C., Bet, P. M., Rhebergen, D., Nurmohamed, M. T., Vinkers, C. H., Penninx, B. W. J. H., Milaneschi, Y., & Lamers, F. (2022) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2022.100585 · Cited by 32
Lipsitz, O., McIntyre, R., Rodrigues, N. B., Kaster, T., Cha, D., Brietzke, E., Gill, H., Nasri, F., Lin, K.-G., Subramaniapillai, M., et al. (2020) · Progress in Neuro-psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110126 · Cited by 22
Stotland, N. L. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.11.007 · Cited by 30
Brignone, M., Diamand, F., Painchault, C., & Takyar, S. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1128404 · Cited by 30
Juneja, K., Bhuchakra, H. P., Sadhukhan, S., Mehta, I., Niharika, A., Thareja, S., Nimmakayala, T., & Sahu, S. (2024) · Cureus · doi:10.7759/cureus.71638 · Cited by 30
Closed-Loop Stimulation in Emotional Circuits for Neuro-Psychiatric Disorders
Widge, A. S., & Moritz, C. T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802452-2.00017-2 · Cited by 30
A key requirement for synaptic Reelin signaling in ketamine-mediated behavioral and synaptic action
Kim, J., Herz, J., Kavalali, E. T., & Monteggia, L. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103079118 · Cited by 30
de Souza, A. G., Lopes, I. S., Filho, A. J. M. C., Cavalcante, T. M. B., Oliveira, J. V. S., de Carvalho, M. A. J., de Lima, K. A., Jucá, P. M., Mendonça, S. S., Mottin, M., et al. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02247-x · Cited by 30
Major Depressive Disorder: New Clinical, Neurobiological, and Treatment Perspectives
Kupfer, D. J., Frank, E., & Phillips, M. L. (2014) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.12.2.217 · Cited by 30
Troppoli, T. A., Zanos, P., Georgiou, P., Gould, T. D., Rudolph, U., & Thompson, S. M. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.11.024 · Cited by 29
Ketamine: stimulating antidepressant treatment?
Malhi, G. S., Byrow, Y., Cassidy, F., Cipriani, A., Demyttenaere, K., Frye, M. A., Gitlin, M., Kennedy, S. H., Ketter, T. A., Lam, R. W., et al. (2016) · BJPsych Open · doi:10.1192/bjpo.bp.116.002923 · Cited by 29
Generalizability of Clinical Trial Results for Adolescent Major Depressive Disorder
Blanco, C., Hoertel, N., Franco, S., Olfson, M., He, J.-P., López, S., González-Pinto, A., Limosin, F., & Merikangas, K. R. (2017) · Pediatrics · doi:10.1542/peds.2016-1701 · Cited by 29
Zhu, J., Hawkins, E., Phillips, K., & Deshpande, L. S. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17134710 · Cited by 27
Ketamine treatment for depression: qualitative study exploring patient views
Jilka, S., Odoi, C. M., Wilson, E., Meran, S., Simblett, S. K., & Wykes, T. (2021) · BJPsych Open · doi:10.1192/bjo.2020.165 · Cited by 29
Mixed-Reality Guidance for Brain Stimulation Treatment of Depression
Leuze, C. W., Yang, G., Hargreaves, B. A., Daniel, B. L., & McNab, J. A. (2018) · IEEE International Symposium on Mixed and Augmented Reality Adjunct (ISMAR-Adjunct) · doi:10.1109/ismar-adjunct.2018.00109 · Cited by 29
A Review of Psychostimulants for Adults With Depression.
Pary, R., Scarff, J. R., Jijakli, A., TOBIAS, C. R., & Lippmann, S. (2015) · Europe PMC (PubMed Central) · Cited by 29
Dominiak, M., Antosik-Wójcińska, A. Z., Wojnar, M., & Mierzejewski, P. (2021) · Pharmaceuticals · doi:10.3390/ph14060582 · Cited by 28
A retrospective examination of care pathways in individuals with treatment-resistant depression
Day, E., Shah, R., Taylor, R., Marwood, L., Nortey, K., Harvey, J., McAllister-Williams, H., Geddes, J. R., Alvaro Barrera, P., Young, A. H., et al. (2021) · BJPsych Open · doi:10.1192/bjo.2021.59 · Cited by 28
Sun, Y., Evans, J., Russell, B., Kydd, R. R., & Connor, B. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.021 · Cited by 28
Bess, K., Adams, J., Watt, M. H., O’Donnell, J. K., Gaynes, B. N., Thielman, N. M., Heine, A. D., Zinski, A., Raper, J. L., & Pence, B. W. (2013) · AIDS Patient Care and STDs · doi:10.1089/apc.2012.0406 · Cited by 28
Self-citationBeyond serotonin: newer antidepressants in the future
Rakesh, G., Pae, C., & Masand, P. S. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1341310 · Cited by 29
Lee, J., Kim, W., Jeon, Y.-J., Lee, S.-B., Lee, D., & Son, C. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00683 · Cited by 28
Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression
Zavaliangos‐Petropulu, A., McClintock, S. M., Khalil, J., Joshi, S. H., Taraku, B., Al‐Sharif, N., Espinoza, R. T., & Narr, K. L. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.04.015 · Cited by 27
Pharmacomicrobiomics of Antidepressants in Depression: A Systematic Review
Brown, L. C., Bobo, W. V., Gall, C. A., Müller, D. J., & Bousman, C. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13071086 · Cited by 27
Krupa, A. J., Chrobak, A. A., Sołtys, Z., Dudek, D., Szewczyk, B., & Siwek, M. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00621-5 · Cited by 27
Estradiol accelerates the effects of fluoxetine on serotonin 1A receptor signaling
Li, Q., Sullivan, N. R., McAllister, C. E., de Kar, L. D. V., & Muma, N. A. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.11.005 · Cited by 27
Dyke, A. M. V., Francis, T. C., Chen, H., Bailey, A. M., & Thompson, S. M. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.03.005 · Cited by 27
RetractedHuang, Y., Lu, K., Lin, Y., Panyod, S., Wu, H., Chang, W.-T., & Sheen, L. (2019) · Food & Function · doi:10.1039/c9fo00601j · Cited by 27
Suzuki, A., Murakami, K., Tajima, Y., Hara, H., Kunugi, A., & Kimura, H. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.06.004 · Cited by 26
Wade, B., Loureiro, J. R., Sahib, A. K., Kubicki, A., Joshi, S. H., Hellemann, G. S., Espinoza, R. T., Woods, R. P., Congdon, E. L., & Narr, K. L. (2022) · Psychological Medicine · doi:10.1017/s0033291722001313 · Cited by 27
Fabbri, C., Crisafulli, C., Calati, R., Albani, D., Forloni, G., Calabrò, M., Martines, R., Kasper, S. F., Zohar, J., Juven‐Wetzler, A., et al. (2017) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-017-0766-1 · Cited by 26
Poleszczyk, A., Rakowicz, M. J., Parnowski, T., Antczak, J. M., & Święcicki, Ł. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.03.084 · Cited by 26
Targeting metabotropic glutamate receptors for rapid-acting antidepressant drug discovery
Musazzi, L. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1822814 · Cited by 26
Maust, D. T., Oslin, D. W., & Thase, M. E. (2013) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.01.030 · Cited by 25
Modeling Heterogeneous Brain Dynamics of Depression and Melancholia Using Energy Landscape Analysis
Regonia, P. R., Takamura, M., Nakano, T., Ichikawa, N., Fermin, A. S. R., Okada, G., Okamoto, Y., Yamawaki, S., Ikeda, K., & Yoshimoto, J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.780997 · Cited by 26
Sánchez‐Carro, Y., de la Torre‐Luque, A., Leal‐Leturia, I., Salvat‐Pujol, N., Massaneda‐Tuneu, C., de Arriba‐Arnau, A., Urretavizcaya, M., Pérez, V., Toll, A., Martínez-Ruiz, A., et al. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110674 · Cited by 25
Losing insurance and psychiatric hospitalizations
Maclean, J. C., Tello‐Trillo, S., & Webber, D. (2022) · Journal of Economic Behavior & Organization · doi:10.1016/j.jebo.2022.11.001 · Cited by 25
Pilon, D., Sheehan, J. J., Szukis, H., Morrison, L., Zhdanava, M., Lefèbvre, P., & Joshi, K. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.100 · Cited by 24
PET imaging of animal models with depressive-like phenotypes
Vazquez-Matias, D. A., de Vries, E. F. J., Dierckx, R., & Doorduin, J. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-06073-4 · Cited by 24
Pence, B. W., Gaynes, B. N., Udedi, M. M., Kulisewa, K., Zimba, C. C., Akiba, C. F., Dussault, J. M., Akello, H., Malava, J., Crampin, A. C., et al. (2024) · The Lancet Global Health · doi:10.1016/s2214-109x(23)00592-2 · Cited by 24
Self-citationHarnessing networks and machine learning in neuropsychiatric care
Cornblath, E. J., Lydon‐Staley, D. M., & Bassett, D. S. (2019) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2018.12.010 · Cited by 24
Oh, H.-M., Lee, J., Kim, S.-W., Oh, Y.-T., Kim, W., Lee, S.-B., Cho, Y.-R., Jeon, Y.-J., Cho, J.-H., & Son, C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01674 · Cited by 24
Botanas, C. J., de la Peña, J. B., Custodio, R. J. P., Peña, I. J. D., Kim, M., Woo, T., Kim, H. J., Kim, H. I., Cho, M. C., Lee, Y. S., et al. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.08.038 · Cited by 24
Vieta, E., Ahmed, N., Arango, C., Cleare, A. J., Demyttenaere, K., Dold, M., Ito, T., Kambarov, Y., Krüger, S., Llorca, P., et al. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.12.013 · Cited by 23
Epstein, I., Szpindel, I., & Katzman, M. A. (2014) · Psychiatry Research · doi:10.1016/s0165-1781(14)70003-4 · Cited by 23
One‐week escitalopram intake alters the excitation–inhibition balance in the healthy female brain
Zsido, R. G., Molloy, E. N., Čėsnaitė, E., Zheleva, G., Beinhölzl, N., Scharrer, U., Piecha, F. A., Regenthal, R., Villringer, A., Nikulin, V. V., et al. (2022) · Human Brain Mapping · doi:10.1002/hbm.25760 · Cited by 23
Cohen, S. E., Zantvoord, J. B., Wezenberg, B. N., Daams, J. G., Bockting, C., Denys, D. A. J. P., & van Wingen, G. A. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.10.042 · Cited by 23
Taraku, B., Woods, R. P., Boucher, M., Espinoza, R. T., Jog, M., Al‐Sharif, N., Narr, K. L., & Zavaliangos‐Petropulu, A. (2023) · Human Brain Mapping · doi:10.1002/hbm.26217 · Cited by 25
Hoertel, N., Strat, Y. L., Limosin, F., Dubertret, C., & Gorwood, P. A. P. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055448 · Cited by 24
Briffault, X., Morgiève, M., & Courtet, P. (2018) · Brain Sciences · doi:10.3390/brainsci8060098 · Cited by 23
Voluntary exercise enables stress resistance in females
Tanner, M. K., Fallon, I. P., Baratta, M. V., & Greenwood, B. N. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.111923 · Cited by 23
Inadequate Response to Antidepressant Treatment in Major Depressive Disorder
Papakostas, G. I., Jackson, W., Rafeyan, R., & Trivedi, M. H. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.ot19037com5 · Cited by 23
Self-citationBakusic, J., Vrieze, E., Ghosh, M., Pizzagalli, D. A., Bekaert, B., Claes, S. J., & Godderis, L. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01136-z · Cited by 23
Fife, D., Reps, J., Cepeda, M. S., Stang, P., Blacketer, M., & Singh, J. (2018) · Heliyon · doi:10.1016/j.heliyon.2018.e00707 · Cited by 22
“Its treatment often includes antidepressant (AD) medications and a substantial proportion of pharmaceutically treated depression (PTD) does not respond adequately to treatment with two or more antidepressant (AD) medications despite adequate dose, duration, and adherence to the antidepressant medications [3, 4, 5, 6].”
BackgroundZarebavani, M., Naeini, F. B., Farahvash, A., Moradi, F., & Dashti, N. (2023) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23311 · Cited by 23
Dmochowski, R. R., Newman, D. K., Rovner, E. S., Zillioux, J. M., Malik, R. D., & Ackerman, A. L. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02625-8 · Cited by 22
Hypnotherapy as Treatment for Depression: A Scoping Review
Vun, J. P. W., Subramaniam, P., Amit, N., Wahab, S. B., & Moustafa, A. A. (2024) · International Journal of Clinical and Experimental Hypnosis · doi:10.1080/00207144.2024.2317193 · Cited by 23
Maust, D. T., Oslin, D. W., & Thase, M. E. (2012) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31826576cf · Cited by 22
Jilka, S., Murray, C., Wieczorek, A., Griffiths, H., Wykes, T., & McShane, R. H. (2019) · BJPsych Open · doi:10.1192/bjo.2019.52 · Cited by 22
Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach
Agin-Liebes, G., & Davis, A. K. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_282 · Cited by 23
Public Insurance and Psychotropic Prescription Medications for Mental Illness
Maclean, J. C., Cook, B. L., Carson, N. J., & Pesko, M. F. (2017) · National Bureau of Economic Research · doi:10.3386/w23760 · Cited by 22
Electroconvulsive therapy: still the gold standard for highly treatment-resistant mood disorders
Goldberg, J. F. (2021) · CNS Spectrums · doi:10.1017/s1092852921000110 · Cited by 22
Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders
Costi, S., Dam, N. T. V., & Murrough, J. W. (2015) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-015-0052-3 · Cited by 21
Yang, P.-S., Peng, H., Lin, T.-B., Hsieh, M., Lai, C., Lee, A., Wang, H.-H., & Ho, Y. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108269 · Cited by 21
Han, C., Wang, G., Chan, S. S. M., Kato, T., Ng, C. H., Tan, W., Zhang, L., Feng, Y., & Liu, C.-Y. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s264799 · Cited by 21
Wu, S., Yang, K.-J., Liu, W., Malau, I. A., Zailani, H., Chang, C., Huang, S., Chang, J. P., Chiu, W., & Su, K. (2024) · Nutrients · doi:10.3390/nu16213688 · Cited by 20
McIntyre, R. S., Johe, K. K., Rong, C., & Lee, Y. L. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1324847 · Cited by 20
Pretreatment Brain Connectome Fingerprint Predicts Treatment Response in Major Depressive Disorder
Fan, S., Nemati, S., Akiki, T. J., Roscoe, J., Averill, C. L., Fouda, S., Averill, L. A., & Abdallah, C. G. (2020) · Chronic Stress · doi:10.1177/2470547020984726 · Cited by 20
Gagne, C., Piot, A., & Brake, W. G. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.797577 · Cited by 23
Deza, M., Lu, T. T., Maclean, J. C., & Ortega, A. (2024) · National Bureau of Economic Research · doi:10.3386/w32227 · Cited by 20
Ortiz, A., & Mulsant, B. H. (2024) · Journal of Medical Internet Research · doi:10.2196/59826 · Cited by 19
Metadata
- Authors
- Gaynes, B. N., Warden, D., Trivedi, M. H., Wisniewski, S. R., Fava, M., & Rush, A. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- The University of Texas Southwestern Medical Center (US)
- University of Pittsburgh (US)
- National University of Singapore (SG)
- Venue
- Psychiatric Services
- Published
- 2009-11
- Volume
- 60
- Issue
- 11
- Pages
- 1439-1445
- ISSN
- 0022-1597 (ISSN-L)
- 1075-2730
- 1557-9700
- OpenAlex
- W2095852687
- Cited by
- 661
- References
- 0
- Citations by year
- 2026: 37 · 2025: 47 · 2024: 57 · 2023: 73 · 2022: 61 · 2021: 58 · 2020: 55 · 2019: 48 · 2018: 41 · 2017: 42 · 2016: 28 · 2015: 33 · 2014: 20 · 2013: 20 · 2012: 16
- FWCI
- 9.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychiatric Services (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Funders
- University of Texas Southwestern Medical Center
- National Institutes of Health (n01mh90003-26-0-0)
- National Institute of Mental Health (N01‐MH‐90003)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- STAR*D, major depressive disorder, antidepressant treatment, treatment-resistant depression, remission, citalopram, antidepressant switching, antidepressant augmentation, primary care, psychiatric clinic
- MeSH terms
- Venlafaxine Hydrochloride, Adolescent, Adult, Aged, Cyclohexanols, Major Depressive Disorder, Female, Humans, Male, Middle Aged, Primidone, Remission Induction, Time Factors, Citalopram, Cognitive Behavioral Therapy, Bupropion, Treatment Outcome, Treatment Failure, Selective Serotonin Reuptake Inhibitors, Dopamine Uptake Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.